Forecasting the Future of Antiphospholipid Syndrome: Prospects and Challenges

Overview

Journal Mo Med

Specialty General Medicine

Date 2023 Oct 16

PMID 37841574

Authors

Aberdeen Taylor

Suresh Kumar

Nicola Pozzi

Affiliations

Soon will be listed here.

Abstract

Antiphospholipid syndrome (APS) is an autoimmune condition affecting young patients, primarily women, negatively impacting their quality of life. APS is under-recognized and underdiagnosed and can have devastating results if untreated, mainly due to uncontrolled thrombosis. Research in the past decades has led to several breakthroughs with important implications for clinical practice. Here, we summarize the state of APS diagnosis, treatment, pathophysiology, and research directions that hold promise for advancing diagnosis and treatment.

References

Kumar S, Chinnaraj M, Planer W, Zuo X, Macor P, Tedesco F . An allosteric redox switch in domain V of β-glycoprotein I controls membrane binding and anti-domain I autoantibody recognition. J Biol Chem. 2021; 297(2):100890. PMC: 8326733. DOI: 10.1016/j.jbc.2021.100890. View

Garcia D, Erkan D . Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med. 2018; 378(21):2010-2021. DOI: 10.1056/NEJMra1705454. View

Cervera R, Piette J, Font J, Khamashta M, Shoenfeld Y, Camps M . Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002; 46(4):1019-27. DOI: 10.1002/art.10187. View

Schulz A, Herrmann E, Ott O, Lindhoff-Last E . Thromboembolic Antiphospholipid Syndrome (APS): Efficacy and Safety of Different Anticoagulants-Results of the APSantiCO Registry. J Clin Med. 2022; 11(16). PMC: 9409774. DOI: 10.3390/jcm11164845. View

van den Hoogen L, Bisoendial R . B-Cells and BAFF in Primary Antiphospholipid Syndrome, Targets for Therapy?. J Clin Med. 2023; 12(1). PMC: 9821657. DOI: 10.3390/jcm12010018. View

Banzato A, Pozzi N, Frasson R, De Filippis V, Ruffatti A, Bison E . Antibodies to Domain I of β(2)Glycoprotein I are in close relation to patients risk categories in Antiphospholipid Syndrome (APS). Thromb Res. 2011; 128(6):583-6. DOI: 10.1016/j.thromres.2011.04.021. View

Agar C, van Os G, Morgelin M, Sprenger R, Marquart J, Urbanus R . Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood. 2010; 116(8):1336-43. DOI: 10.1182/blood-2009-12-260976. View

Cohen H, Hunt B, Efthymiou M, Arachchillage D, Mackie I, Clawson S . Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016; 3(9):e426-36. PMC: 5010562. DOI: 10.1016/S2352-3026(16)30079-5. View

Khamashta M, Cuadrado M, Mujic F, Taub N, Hunt B, Hughes G . The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med. 1995; 332(15):993-7. DOI: 10.1056/NEJM199504133321504. View

10.

Lackner K, Muller-Calleja N . Antiphospholipid Antibodies: Their Origin and Development. Antibodies (Basel). 2019; 5(2). PMC: 6698834. DOI: 10.3390/antib5020015. View

11.

Nayak L, Sweet D, Thomas A, Lapping S, Kalikasingh K, Madera A . A targetable pathway in neutrophils mitigates both arterial and venous thrombosis. Sci Transl Med. 2022; 14(660):eabj7465. PMC: 10318551. DOI: 10.1126/scitranslmed.abj7465. View

12.

Meroni P, Borghi M, Raschi E, Tedesco F . Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011; 7(6):330-9. DOI: 10.1038/nrrheum.2011.52. View

13.

Vandevelde A, Chayoua W, de Laat B, Moore G, Musial J, Zuily S . Added value of antiphosphatidylserine/prothrombin antibodies in the workup of thrombotic antiphospholipid syndrome: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. J Thromb Haemost. 2022; 20(9):2136-2150. DOI: 10.1111/jth.15785. View

14.

Manukyan D, Muller-Calleja N, Jackel S, Luchmann K, Monnikes R, Kiouptsi K . Cofactor-independent human antiphospholipid antibodies induce venous thrombosis in mice. J Thromb Haemost. 2016; 14(5):1011-20. DOI: 10.1111/jth.13263. View

15.

Cervera R, Serrano R, Pons-Estel G, Ceberio-Hualde L, Shoenfeld Y, de Ramon E . Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients. Ann Rheum Dis. 2014; 74(6):1011-8. DOI: 10.1136/annrheumdis-2013-204838. View

16.

de Groot P, Urbanus R . The significance of autoantibodies against β2-glycoprotein I. Blood. 2012; 120(2):266-74. DOI: 10.1182/blood-2012-03-378646. View

17.

Muller-Calleja N, Hollerbach A, Royce J, Ritter S, Pedrosa D, Madhusudhan T . Lipid presentation by the protein C receptor links coagulation with autoimmunity. Science. 2021; 371(6534). PMC: 9014225. DOI: 10.1126/science.abc0956. View

18.

Chaturvedi S, Braunstein E, Yuan X, Yu J, Alexander A, Chen H . Complement activity and complement regulatory gene mutations are associated with thrombosis in APS and CAPS. Blood. 2019; 135(4):239-251. PMC: 6978159. DOI: 10.1182/blood.2019003863. View

19.

Dabit J, Valenzuela-Almada M, Vallejo-Ramos S, Duarte-Garcia A . Epidemiology of Antiphospholipid Syndrome in the General Population. Curr Rheumatol Rep. 2022; 23(12):85. PMC: 8727975. DOI: 10.1007/s11926-021-01038-2. View

20.

Devreese K . Testing for antiphospholipid antibodies: Advances and best practices. Int J Lab Hematol. 2020; 42 Suppl 1:49-58. DOI: 10.1111/ijlh.13195. View